Skip to main content

Advertisement

Table 1 Clinical features of previously published patients with the e6a2 transcripts

From: Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis

Age/Sex Disease Transcripts Treatment Response to TKI Clinical course/outcome References
80/M Secondary AML e6a2 Dasatinib, Imatinib Reduction in BCR-ABL1 transcripts Death from pancreatic tumor Brattås et al., present
50/M Chronic phase CML e6a2 α interferon, Cytarabine Not reported Not reported [29]
57/M Chronic phase CML e6a2 Imatinib, Dasatinib Minimal cytogenetic response Not reported [30]
53/F De novo AML e6a2 Anthracycline based chemotherapy, Dasatinib, Imatinib Complete molecular response Not reported [31]
76/M Chronic phase CML e6a2 Hydroxyurea, α interferon Not reported Death from cerebral ictus [32]
65/M Blast phase CML e6a2 Hydroxyurea, Imatinib Reduction of WBC after 30 days Death from pneumonia [33]
41/M Chronic phase CML e6a2 Hydroxyurea, Irradiation Not reported Death from sepsis 16 days after ASCT [34]
55/F De novo AML e6a2 ASCT, Imatinib, Dasatinib, Nilotinib Reduction of BCR-ABL1 transcripts Complete molecular remission [35]
48/F Blast crisis CML e6a2 Imatinib Reduction of BCR-ABL1 transcripts Complete molecular remission [36]
67/M Chronic phase CML e6a2 Imatinib Complete hematologic and cytogenetic response Hematologic remission [37]
37/M Chronic phase CML e6a1, e1a2 Imatinib Partial molecular response Disease stabilized on imatinib [38]
48/M Chronic phase CML e6a2 Imatinib, Hydroxyurea, Dasatinib Disease progression and resistance mutations Death from blast crisis [39]
42/M Accelerated phase CML e6a2 Imatinib, Dasatinib, ASCT Persistent disease Developed myeloid sarcoma [40]
36/M Chronic phase CML e6a2, e1a2 Imatinib, Nilotinib, ASCT Imatinib, Nilotinib Progression to acute phase Complete cytogenetic remission [41]
64/F CMML e6a2 Imatinib Reduction of BCR-ABL1 transcripts Not reported [42]
Not reported CMML e6a2 Induction chemotherapy, Dasatinib, Nilotinib Disease progression despite reduction of Ph + clone Death due to disease progression [43]
Not reported Blast crisis CML e6a2 Dasatinib Reduction of BCR-ABL1 transcripts Not reported [44]
77/F Accelerated phase CML e6a2 Imatinib, Nilotinib Complete hematological and cytogenetic response Disease stabilized on nilotinib [45]
53/F De novo AML e6a2 Imatinib, Dasatinib, ASCT Complete hematological and cytogenetic response Disease stabilized on dasatitinib [46]
51/M Accelerated phase CML e6a2 Hydroxyurea, Imatinib, ASCT Persistent disease Not evidence of BCR-ABL1 transcripts day + 30 after the second transplant [47]
43/M CML e6a2 Imatinib Complete hematological and cytogenetic response Not reported [48]
  1. Abbreviations: AML acute myeloid leukemia, ASCT allogenic stem cell transplantation, CML chronic myeloid leukemia, CMML chronic myelomonocytic leukemia, CMR complete molecular response, F Female, M Male, TKI tyrosine kinase inhibitors, WBC white blood cells